# OnCo record nct07750158 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07750158/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07750158", "NCT07750158" ;
  schema:name "Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease"@en ;
  schema:alternateName "STELLAR-316"@en ;
  schema:description "A phase 3 trial of zanzalintinib and pembrolizumab in colorectal cancer, run by Exelixis, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07750158/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07750158> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/zanzalintinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/exelixis/> .